Literature DB >> 8369375

Selection designs for pilot studies based on survival.

P Y Liu1, S Dahlberg, J Crowley.   

Abstract

In cancer clinical trials new regimens are typically tested for antitumor activities in patients with advanced disease. The promising ones are then compared to the standard treatment in a randomized study, sometimes performed on patients with earlier-stage disease. When there are multiple promising regimens, it may not be possible to compare all of them to the control group because of the prohibitive sample size and study length requirements. We propose a design that uses the Cox regression model to select a best treatment based on survival before the randomized comparison. Sample sizes for an asymptotically correct selection probability of .90 are presented for Weibull survival distributions with parameters in a range we consider to be of practical interest. Simulations verify that the asymptotic approximations to the correct selection probabilities are quite satisfactory. Simulations also indicate that the procedure is reasonably robust to the proportional hazards assumption. In contrast to the two-stage screening design recommended by Schaid, Wieand, and Therneau (1990, Biometrika 77, 507-513), our design has the advantage of fitting naturally to a progression of cancer trials where the selection and comparison phases are carried out on different populations of patients. When the population of interest stays the same, our design can be more conservative on the average but offers the opportunity to base the comparative trial on the experience gained during the selection phase.

Entities:  

Mesh:

Year:  1993        PMID: 8369375

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  10 in total

1.  Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.

Authors:  Roy S Herbst; Karen Kelly; Kari Chansky; Philip C Mack; Wilbur A Franklin; Fred R Hirsch; James N Atkins; Shaker R Dakhil; Kathy S Albain; Edward S Kim; Mary Redman; John J Crowley; David R Gandara
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

Review 2.  Statistics in clinical trials.

Authors:  Stephanie J Green; Donna K Pauler
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

Review 3.  Randomized phase II trials: a long-term investment with promising returns.

Authors:  Manish R Sharma; Walter M Stadler; Mark J Ratain
Journal:  J Natl Cancer Inst       Date:  2011-06-27       Impact factor: 13.506

4.  Randomized phase II study of sequential carboplatin plus paclitaxel and gefitinib in chemotherapy-naïve patients with advanced or metastatic non-small-cell lung cancer: Long-term follow-up results.

Authors:  Emi Kubo; Noboru Yamamoto; Hiroshi Nokihara; Yutaka Fujiwara; Hidehito Horinouchi; Shintaro Kanda; Yasushi Goto; Yuichiro Ohe
Journal:  Mol Clin Oncol       Date:  2016-11-09

Review 5.  Randomized phase II designs.

Authors:  Larry Rubinstein; John Crowley; Percy Ivy; Michael Leblanc; Dan Sargent
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

6.  Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).

Authors:  J B Vermorken; F Peyrade; J Krauss; R Mesía; E Remenar; T C Gauler; U Keilholz; J P Delord; P Schafhausen; J Erfán; T H Brümmendorf; L Iglesias; U Bethe; C Hicking; P M Clement
Journal:  Ann Oncol       Date:  2014-03       Impact factor: 32.976

7.  Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia.

Authors:  Christina Yap; Andrew Pettitt; Lucinda Billingham
Journal:  BMC Med Res Methodol       Date:  2013-07-03       Impact factor: 4.615

8.  Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.

Authors:  I Sekine; H Nokihara; K Takeda; Y Nishiwaki; K Nakagawa; H Isobe; K Mori; K Matsui; N Saijo; T Tamura
Journal:  Br J Cancer       Date:  2008-02-05       Impact factor: 7.640

9.  Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Authors:  Seth P Lerner; Dean F Bajorin; Colin P Dinney; Jason A Efstathiou; Susan Groshen; Noah M Hahn; Donna Hansel; David Kwiatkowski; Michael O'Donnell; Jonathan Rosenberg; Robert Svatek; Jeffrey S Abrams; Hikmat Al-Ahmadie; Andrea B Apolo; Joaquim Bellmunt; Margaret Callahan; Eugene K Cha; Charles Drake; Jonathan Jarow; Ashish Kamat; William Kim; Margaret Knowles; Bhupinder Mann; Luigi Marchionni; David McConkey; Lisa McShane; Nilsa Ramirez; Andrew Sharabi; Arlene H Sharpe; David Solit; Catherine M Tangen; Abdul Tawab Amiri; Eliezer Van Allen; Pamela J West; J A Witjes; Diane Zipursky Quale
Journal:  Bladder Cancer       Date:  2016-04-27

10.  Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.

Authors:  James X Chen; E Paul Wileyto; Michael C Soulen
Journal:  Trials       Date:  2018-07-17       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.